Creative Medical Technology - התחייבויות לטווח ארוך של החברה CELZ

Creative Medical Technology (CELZ) is developing stem cell-based urological treatments, leveraging intellectual property protections to secure future revenues. Patents and stringent FDA oversight create a high barrier to entry, which amplifies the influence of lobbyists. Demand within private clinics is rising, while the long-term debt ratio stands at 0.00. The price trend illustrated in this chart confirms the expansion of regenerative medicine.

The credit profile determines capital stability when scaling biomedical projects. This metric captures the aggregate of obligations with a maturity of over one year, reflecting the long-term financial burden. For Creative Medical Technology (CELZ), such funds are critical for financing costly clinical phases and protecting patent barriers. The current value of 0.00 demonstrates the level of borrowing used to secure a technological advantage. By analyzing the state of the firm's long-term borrowed funds, an investor assesses the balance between expansion and solvency.